Drug Profile
Research programme: peptidomimetic therapeutics - Ra Pharmaceuticals
Alternative Names: Cyclomimetics™; RA 101348Latest Information Update: 07 Apr 2020
Price :
$50
*
At a glance
- Originator Ra Pharmaceuticals
- Class Peptidomimetics; Small molecules
- Mechanism of Action Complement C5 inhibitors; Kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hereditary angioedema; Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 02 Apr 2020 Ra Pharmaceuticals has been acquired by UCB
- 28 Jan 2019 No recent reports of development identified for preclinical development in Paroxysmal-nocturnal-haemoglobinuria in USA (SC)
- 16 Jul 2016 No recent reports of development identified for research development in Hereditary-angioedema in USA (PO)